CD8A and melanoma: In patients with advanced melanoma, a high baseline proportion of terminally differentiated effector memory CD8 was negatively associated with OS upon anti–Cytotoxic T-Lymphocyte-Associated protein-4 (CTLA-4) treatment (57).